Emergent BioSolutions (NYSE:EBS) initiates two new programs aimed at treating and preventing coronavirus infection based on its hyperimmune platforms.
Human polyclonal hyperimmune with antibodies to
SARS-CoV-2 (COVID-HIG) for the potential treatment of severely ill
hospitalized patients and protection for at-risk people.
Equine-derived polyclonal hyperimmune with
antibodies to SARS-CoV-2 (COVID-EIG) for the potential treatment of
severely ill hospitalized patients.
Both candidates will be derived from plasma,
humans with anti-SARS-CoV-2 antibodies and horses immunized with
anti-SARS-CoV-2 antibodies.
The company has launched plasma collections with a
goal of manufacturing clinical material within the next four or five
months. A clinical trial may start as early as Q3.
Shares up 1% after hours.
https://seekingalpha.com/news/3550757-emergent-biosolutions-to-develop-hyperimmune-candidates-for-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.